Salivary IL-17A, IL-17F, and TNF-α Are Associated with Disease Advancement in Patients with Oral and Oropharyngeal Cancer

Figure 2

Differences in concentrations of IL-17A, IL-17F, and TNF-α between patients with head and neck cancers depending on T or N parameters. (a) There was a significant difference in salivary concentration of IL-17A () between patients with different sizes of primary tumor; post-hoc tests showed significant differences between stage T4 patients and T1-T2 as well as T3 patients. (b) There was a significant difference in salivary concentration of TNF-α () between stages and post hoc tests showed significant differences between stage T4 patients and T1-T2 patients. (c) There was a significant difference in salivary concentration of IL-17A () between stages and post hoc tests showed significant differences between N2-N3 patients and N0 patients. (d) There was a significant difference in salivary concentration of IL-17F () between stages, and post hoc tests showed significant differences between N2-N3 patients and N0 patients. (e) There was a significant difference in salivary concentration of TNF-α () between stages, and post hoc tests showed significant differences between N1 patients and N0 patients. , , _median.

(a)

(b)

(c)

(d)

(e)